Currently, approved checkpoint inhibitors target mainly the programmed cell death protein 1 (PD-1) axis or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to reinvigorate anti-tumour immunity [1]. This evidence concerns the gene CTLA4 and neoplasm.